文献速递儿童青少年精神焦虑、强迫与应激相关障碍

儿童焦虑障碍药物与CBT序贯治疗的实用性SMART研究

A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial.
PubMed 文献 · Am J Psychiatry · 2026-06-24

该24周单盲序贯多重分配随机试验在基层和心理健康诊所纳入316名8-17岁严重焦虑青少年,随机接受氟西汀或暴露式CBT初始治疗12周,未缓解者再随机继续原治疗或联合治疗。结果显示24周青少年报告SCARED评分总体下降31.7%,初始治疗间无显著差异,联合治疗对12周未缓解者未优于继续单药,但CBT起始后联合治疗在部分指标上显著分离,且种族差异影响治疗序列获益。

要点

  • 氟西汀与CBT初始治疗24周症状改善无显著差异,CBT有非显著优势。
  • 12周未缓解者联合治疗未显著优于继续单药治疗。
  • 非西班牙裔白人青少年从氟西汀起始并持续获益更多,少数族裔从12周后转联合治疗获益更多。

核心结论

  • 对于儿童焦虑障碍,氟西汀、CBT、联合治疗及不同序贯方案带来的症状减轻程度相似。
  • 患者、家庭和临床医生有多种治疗选择,可根据利益相关者偏好优化结局。

研究设计与样本

  • 24周单盲序贯多重分配随机试验(SMART),在基层和心理健康诊所开展,设两个12周治疗阶段。
  • 纳入316名8-17岁符合DSM-5焦虑障碍诊断、未接受焦虑治疗且阅读水平至少二年级的青少年。
  • 第一阶段随机分配至氟西汀或CBT,第二阶段随机分配至继续初始治疗或联合治疗。
  • 主要结局为青少年报告41项SCARED评分,次要结局包括家长报告SCARED和青少年及家长报告Child Anxiety Impact Scale评分。

主要发现

  • 24周内青少年报告SCARED评分总体下降31.7%。
  • 初始治疗间改善无显著差异,CBT相对药物有非显著优势(24周平均组间变化差异1.45,95%CI=-2.25, 5.16)。
  • 12周未缓解者中,联合治疗24周改善未优于继续单药治疗(组间基线平均变化差异-2.74,95%CI=-6.53, 1.05)。
  • CBT起始后联合治疗在24周部分指标上显著区别于其他序列。
  • 非西班牙裔白人青少年从氟西汀起始并持续治疗获益更多,种族和族裔少数青少年从12周后转联合治疗获益更多。

关键数值与推荐

  • 纳入标准:DSM-5焦虑障碍、年龄8-17岁、阅读水平至少二年级、未接受焦虑治疗。
  • 主要结局为青少年报告41项SCARED评分。
  • 12周未缓解者定义为未达到缓解标准。

临床怎么用

  • 临床医生可依据患者和家庭偏好选择氟西汀、CBT或联合治疗及序贯方案。
  • 对12周未缓解者,继续单药或转为联合治疗均为合理选择。
  • 需考虑种族和族裔背景对治疗序列获益的潜在影响。

局限性

  • 单盲设计可能引入偏倚。
  • 样本具有高社会人口学劣势和共病诊断,外推需谨慎。
  • 部分亚组分析可能统计效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinicians treating pediatric anxiety disorders have inadequate information to decide which evidence-based treatment should initiate care and what strategies to adopt when initial care proves to be insufficient. The authors sought to determine whether beginning treatment with fluoxetine or exposure-based CBT yielded better outcomes, and, if 3 months of treatment failed to produce remission, whether optimizing the initial treatment or adding the other treatment modality (combination therapy) yielded better outcomes. METHODS: This 24-week single-blind sequential multiple assignment randomized trial (SMART), conducted in primary care and mental health clinics, employed two 12-week treatment stages: randomization to fluoxetine or cognitive-behavioral therapy (CBT) followed by randomization to either continued initial treatment or combination therapy. Eligibility criteria included a DSM-5 anxiety disorder; age 8-17; at least 2nd-grade reading level; and not receiving anxiety treatments. The primary outcome was score on the youth-report 41-item Screen for Child Anxiety Related Emotional Disorders (SCARED). Secondary outcomes were score on the parent-report SCARED and scores on the youth- and parent-report Child Anxiety Impact Scale. The authors hypothesized better outcomes from initial treatment with fluoxetine followed by combination treatment. RESULTS: A total of 316 youths with severe anxiety who had high levels of sociodemographic disadvantage and co-occurring diagnoses were randomized. Overall, youth-reported SCARED scores declined 31.7% over the 24-week trial. Improvement did not differ significantly by initial treatment, although CBT afforded a nonsignificant advantage over medication (24-week difference in mean group change: 1.45, 95% CI=-2.25, 5.16). In week-12 nonremitters, combination treatment did not yield superior week-24 improvement over continuing monotherapy (group difference in mean change from baseline: -2.74, 95% CI=-6.53, 1.05). Initial treatment with CBT followed by combination therapy significantly separated from other sequences on a subset of measures over 24 weeks. Non-Hispanic White youths benefited more from initiating treatment with fluoxetine and continuing it after week 12, whereas racial and ethnic minority youths benefited more from transitioning to combination therapy after week 12. CONCLUSIONS: This pragmatic SMART study shows that symptom reduction is similar for fluoxetine, CBT, their combination, and variations in sequencing when delivered to youths with anxiety disorders. Patients, families, and clinicians have a range of treatment options and may optimize outcomes by stakeholder preference.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Peterson BS, West AE, Weersing VR, et al. A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial. Am J Psychiatry. 2026. PMID: 42337414. doi:10.1176/appi.ajp.20251037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。